$NBIO - announced today a collaboration to develop an alternative delivery mechanism for patients who can benefit from Pritumumab ("PTB"
, Nascent's lead monoclonal antibody cancer treatment asset, which is now in Phase II clinical research for the treatment of Brain Cancer.
https://finance.yahoo.com/news/nascent-collab...00958.html